Skip to main content
CBSC logo

Cardiac Biotech Solutions Inc. (CBSC) Stock Price & Analysis

Cardiac Biotech Solutions Inc. (CBSC) — price $0.035 (0.00%), as of the Nov 19, 2026 trading session; market cap $5.97M.

Educational signal · not a buy or sell recommendation · How to read this

$0.035 $0.00 (0.00%) Market Cap $5.97M

Cardiac Biotech Solutions Inc. · CBSC

Cardiac Biotech Solutions Inc. focuses on ambulatory non-invasive cardiac monitoring. The company provides FDA and CE cleared EKG devices, cloud-based software, and smartphone apps.

Price as of Nov 19, 2026

Key Statistics

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • RGNT · Regentis Biomaterials Ltd. · 64 /100
  • LUCY · Innovative Eyewear, Inc. · 21 /100
  • WOK · WORK Medical Technology Group Ltd. · 30 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$0.035
Change on the day0.00%
52-week range$0.016 – $0.063
Market capitalisation$5.97M—
Shares traded on the day15.0K

Price & events

Other perspectives

Council score for Cardiac Biotech Solutions (CBSC): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

5 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Simons-style lens (simulated) Jim Simons Favorable read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Unfavorable read

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Strong
Debt/Equity Strong
ROE Strong
Gross Margin Negative

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Cardiac Biotech Solutions (CBSC), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Cardiac Biotech Solutions Inc. (CBSC) is the company analyzed here. It employs 4 people and is led by Charles K. Martin. In Q1 FY2026 it reported revenue of $40,154 and net income of -$137,173. The market values it at $5.97M.

2 · Latest results

What do the latest results show for Cardiac Biotech Solutions (CBSC)?

Short answer · as of

The most recent reported quarter, Q1 FY2026, carried revenue of $40,154.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q1 FY2026$40,154-$137,173$0.00 (diluted)
Q4 FY2025$40,460-$103,048-$0.0009 (diluted)
Q3 FY2025$40,329-$573,681-$0.0035 (diluted)
Q2 FY2025$26,868-$40,505$0.00 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Cardiac Biotech Solutions (CBSC)?

Short answer · as of

The distress and quality screens read Piotroski F 2. Trailing ratios: ROE 39.2% · current ratio 0.23 · earnings yield -14.7% · free-cash-flow yield -11.9%.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held CBSC in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported CBSC in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What Investors Ask About Cardiac Biotech Solutions (CBSC)

These answers are editorial: 1 of these 8 answers is drawn from the CBSC research dossier (written Mar 18, 2026 by gemini-2.0-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.

Is CBSC a good stock to buy?

Stock Expert AI does not rate CBSC buy, sell or hold. Cardiac Biotech Solutions Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the CBSC stock price today?

The last price recorded for Cardiac Biotech Solutions Inc. (CBSC), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the main risks for CBSC?

Cardiac Biotech Solutions Inc. faces several risks, including competition from established players in the cardiac monitoring market, regulatory changes and compliance requirements, and technological advancements that could render existing products obsolete.

What are the key factors to evaluate for CBSC?

Evaluate CBSC on fundamentals, analyst consensus, and risk factors. FDA and CE cleared EKG devices provide a regulatory advantage in the ambulatory cardiac monitoring market. Not financial advice.

How frequently does CBSC data refresh on this page?

CBSC's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven CBSC's recent stock price performance?

Cardiac Biotech Solutions Inc. (CBSC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: FDA and CE cleared EKG devices. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider CBSC overvalued or undervalued right now?

Cardiac Biotech Solutions Inc. (CBSC) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research CBSC before investing?

Before investing in Cardiac Biotech Solutions Inc. (CBSC), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 18, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 13 figures on this page — 7 from Financial Modeling Prep (FMP) and 6 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.